A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

Japan's health ministry has announced formal approval for the domestic manufacture and sale of two products for the treatment of heart disease and Parkinson's disease using iPS cells. It means such ...

Conditional approval marks a global milestone in regenerative medicine; treatments could reach patients this summer - Anadolu ...

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients ...

Sumitomo Dainippon Pharma Co ( (JP:4506)) just unveiled an announcement. Sumitomo Pharma has received conditional and time-limited approval in Japan to manufacture and market AMCHEPRY, an allogeneic ...

Japan has approved two pioneering stem-cell therapies for the treatment of Parkinson’s disease and severe heart failure, marking a major milestone in ...

Japan has formally approved the world’s first regenerative medical products utilizing induced pluripotent stem (iPS) cells, paving the way for use in patients as early as this summer.

Japan has approved pioneering stem-cell treatments for Parkinson's and severe heart failure, marking a global first in commercially available medical products using iPS cells.

A Parkinson's disease treatment based on induced pluripotent stem cells (iPS) has been officially approved in Japan – as announced by ...

Tokyo-based K Pharma Inc. and Nikon Cell Innovation Co. on Tuesday signed a basic agreement on a new clinical trial project using induced pluripotent stem (iPS) cells to treat spinal cord injuries.

Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...